Alexander Gutin

Medication adherence following pharmacogenomic testing in patients with major depressive disorder

Andria L. Del Tredici, Holly L. Johnson, W. Brady DeHart, Alexander Gutin et autres

us, de (code pays fourni par la source)

Abstract CT280: A pragmatic study of the clinical utility of genomic classifiers in guiding prostate cancer treatment decisions: Impact of treatment selection, oncologic outcomes, and treatment-related adverse events (PROMPT-Bx)

Brent Mabey, Lauren Lenz, Thaylon Davis, Alexander Gutin et autres

Abstract Background: Prostate cancer (PCa) risk models based on clinicopathological features have been widely adopted by clinicians to inform treatment decisions. Prolaris provides greater prognostic power for evaluating risk of distant metastases and PCa-specific mortality than traditional risk models. Evidence is limited …

us (code pays fourni par la source)

Abstract 3587: Independent validation of polygenic risk scores for overall and triple-negative breast cancer among high-risk African American women.

Yijia Sun, Timothy Simmons, J. Li, Armaan Jamal et autres

Abstract Background: Polygenic risk scores (PRSs) are emerging tools for stratifying breast cancer (BC) risk. We developed PRSs of overall BC and triple-negative BC (TNBC) risk in women of African ancestry, using case-control data from studies unselected for family history. PRS could …

us, de (code pays fourni par la source)

The Prolaris test on diagnostic biopsy for localized prostate cancer prognosis across risk groups and management: An individual participant data meta-analysis.

Steven Monda, Matthew J. Schiewer, Lauren Lenz, Wyatt Clegg et autres

394 Background: Tools to risk stratify localized prostate cancer are limited. We sought to conduct a robust, individual participant data (IPD) meta-analysis of the performance of Prolaris from diagnostic biopsy in localized prostate cancer. Prolaris is based on a combined clinical risk …

us, es (code pays fourni par la source)

Abstract PS3-01-03: Interactions between polygenic variants and clinical factors as predictors of breast cancer risk in women of self-reported Black/African ancestry

Timothy Simmons, E. Hughes, Matthew Kucera, Alexander Gutin

Abstract Background Polygenic risk scores (PRSs) combine information from single-nucleotide polymorphisms (SNPs) across the genome to explain a substantial portion of genetic breast cancer (BC) susceptibility. In previous studies, a multiple-ancestry PRS (MA-385) based on 56 ancestry-informative and 329 BC-associated SNPs was …

de, us (code pays fourni par la source)

Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder

Daniel Hain, Andria L. Del Tredici, Ryan Griggs, Rebecca Law et autres

Background: In patients with major depressive disorder (MDD), achieving remission and/or response may take many months because of the lengthy trial-and-error process often needed to identify effective medication. Pharmacogenomic testing is a prescribing tool that has been shown to improve remission and …

us (code pays fourni par la source)

Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With Depression

Renee E. Albers, M Dyer, Matthew Kucera, Daniel Hain et autres

PURPOSE/BACKGROUND: Multiple meta-analyses have suggested that pharmacogenomic (PGx) testing may be a valuable tool to improve clinical outcomes for patients with major depressive disorder (MDD) who have failed at least one treatment. However, these meta-analyses included studies with different PGx tests and …

us, de (code pays fourni par la source)

Abstract PS16-01: Longitudinal validation in the UK Biobank of a breast cancer risk assessment tool that combines a polygenic score for all ancestries with traditional risk factors

Timothy Simmons, Elisha Hughes, Srikanth Jammulapati, Dmitry Pruss et autres

Abstract Background: Polygenic risk scores (PRS) have been shown to improve predictive accuracy when incorporated into traditional breast cancer (BC) risk assessment tools. However, most PRS have demonstrated suboptimal performance among women of non-European ancestry. We improved a previously reported multiple-ancestry PRS …

Abstract RF1-06: Association of polygenic-based breast cancer risk prediction with patient management

Katie Johansen Taber, Sarah Ratzel, Elisha Hughes, Alexander Gutin et autres

Abstract Background:A breast cancer (BC) risk predictor that combines the Tyrer-Cuzick (TC) risk model with a polygenic risk score (“combined risk score” or CRS) has been shown to significantly improve risk prediction over TC alone. Guidelines recommend that individuals predicted to have …

The importance of algorithms when determining homologous recombination deficiency status in ovarian tumors.

Kirsten M. Timms, Lauren Lenz, Breanna Roscow, Victor Abkevich et autres

e15166 Background: Ovarian tumors with homologous recombination deficiency (HRD) respond better to PARP inhibitor and platinum-based chemotherapy treatment compared to those that are HR proficient. Markers of genomic instability can help predict HRD status. MyChoice is an FDA-approved genomic instability score (GIS) …

us (code pays fourni par la source)

Association of an ancestry-specific variant near the ESR1 gene with cancer risk and breast density in women of self-reported Hispanic ancestry.

Elisha Hughes, Allison W. Kurian, Eudora Hu, Matthew Kucera et autres

10513 Background: A single-nucleotide polymorphism (SNP), rs140068132, located in the 6q25 region near the ESR1 gene, is common in self-reported Hispanic women but rare or absent in other populations. Previous studies have shown that rs140068132 is associated with a significantly reduced risk …

us (code pays fourni par la source)

Interactions between polygenic variants and clinical factors as predictors of breast cancer risk in the UK Biobank.

Timothy Simmons, Elisha Hughes, Sandhya Pruthi, Srikanth Jammulapati et autres

10512 Background: Polygenic risk scores (PRSs) combine information from single-nucleotide polymorphisms (SNPs) across the genome to explain substantial genetic breast cancer (BC) susceptibility. Previous studies have demonstrated that a multiple-ancestry PRS (MA-385) based on 56 ancestry-informative and 329 BC-associated SNPs is accurate …

us (code pays fourni par la source)